🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Market value of Nvidia and TSMC surges in October on strong AI chip demand

Published 2024-11-04, 06:57 a/m
© Reuters. A person gestures next to an Nvidia Spectrum-X at COMPUTEX in Taipei, Taiwan June 4, 2024. REUTERS/Ann Wang/File Photo
NVDA
-
TSM
-

(Reuters) - Nvidia (NASDAQ:NVDA) led a surge in market value among global firms in October, buoyed by unrelenting demand for its new supercomputing artificial intelligence chips as more companies integrate AI into their daily operations.

Nvidia's market cap rose 9.3% in October to $3.26 trillion, while the company's supplier, TSMC, saw its market value increase 6.5% to $832.8 billion. The gains came after the world's largest contract chipmaker posted better-than-expected third-quarter earnings and gave a robust outlook for AI demand.

Apple (NASDAQ:AAPL) briefly ceded its top global market capitalization spot to Nvidia, with a 3% decline to $3.4 trillion last month on a modest growth forecast and sluggish sales in China, before bouncing back.

The market values of Meta (NASDAQ:META) Platforms and Microsoft (NASDAQ:MSFT) fell in October after both companies warned about escalating AI costs.

Mark Haefele, chief investment officer at UBS Global Wealth Management, maintained his positive outlook on AI, advising investors to use near-term volatility as an opportunity to increase exposure to quality AI stocks.

"We continue to favor select semi names and big tech, and we expect our AI portfolio to deliver 35% earnings growth in 2024 and 25% in 2025."

© Reuters. A person gestures next to an Nvidia Spectrum-X at COMPUTEX in Taipei, Taiwan June 4, 2024. REUTERS/Ann Wang/File Photo

In Asia, the market value of Tencent Holdings fell 9% to $483 billion in October, carried by a wider decline in Chinese shares due to sluggish economic data, geopolitical tensions and as investors paused to assess government support measures.

U.S. drugmaker Eli Lilly (NYSE:LLY)'s market value dropped 6.45% to $787.6 billion last month as its quarterly sales of high-profile weight-loss and diabetes drugs failed to meet Wall Street's sales estimates, resulting in a sharp decline in its shares.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.